(1.17%) 5 123.39 points
(1.16%) 38 670 points
(1.96%) 16 151 points
(-0.65%) $78.44
(5.06%) $2.14
(-0.36%) $2 301.40
(-0.89%) $26.59
(-0.06%) $962.00
(-0.43%) $0.928
(-1.33%) $10.85
(-0.12%) $0.797
(0.40%) $91.49
3 days till quarter result
(bmo 2024-05-06)
Expected move: +/- 12.28%
0.56% $ 4.51
@ $5.48
Emitido: 14 feb 2024 @ 15:23
Retorno: -17.72%
Señal anterior: feb 14 - 12:19
Señal anterior:
Retorno: 1.96 %
Live Chart Being Loaded With Signals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema...
Stats | |
---|---|
Volumen de hoy | 600 904 |
Volumen promedio | 3.26M |
Capitalización de mercado | 929.52M |
EPS | $0 ( 2024-05-01 ) |
Próxima fecha de ganancias | ( $-0.230 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.82 |
ATR14 | $0.00900 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Thackray Helen M. | Sell | 7 525 | Common Stock |
2024-02-29 | Milano Vincent | Buy | 999 | Common Stock |
2024-02-29 | Heggie Theresa | Buy | 999 | Common Stock |
2024-01-03 | Stonehouse Jon P | Sell | 20 000 | Common Stock |
2024-01-03 | Stonehouse Jon P | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
75.18 |
Last 100 transactions |
Buy: 4 343 991 | Sell: 822 588 |
Volumen Correlación
BioCryst Pharmaceuticals Correlación
10 Correlaciones Más Positivas | |
---|---|
NAKD | 0.945 |
SNGX | 0.941 |
GSMG | 0.94 |
MICS | 0.938 |
CSSEP | 0.932 |
TENX | 0.931 |
GRNA | 0.931 |
IRBT | 0.93 |
BCYC | 0.93 |
BHTG | 0.928 |
10 Correlaciones Más Negativas | |
---|---|
NCAC | -0.944 |
MLTX | -0.944 |
LMNR | -0.944 |
TETC | -0.941 |
PPYAU | -0.938 |
SJ | -0.935 |
INSE | -0.935 |
PLBC | -0.933 |
ALTR | -0.932 |
RCEL | -0.932 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
BioCryst Pharmaceuticals Correlación - Moneda/Commodity
BioCryst Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $331.41M |
Beneficio Bruto: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2023 |
Ingresos: | $331.41M |
Beneficio Bruto: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2022 |
Ingresos: | $270.83M |
Beneficio Bruto: | $264.23M (97.57 %) |
EPS: | $-1.330 |
FY | 2021 |
Ingresos: | $157.17M |
Beneficio Bruto: | $149.91M (95.38 %) |
EPS: | $-1.030 |
Financial Reports:
No articles found.
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico